Pharsight

Valchlor is owned by Helsinn.

Valchlor contains Mechlorethamine Hydrochloride.

Valchlor has a total of 6 drug patents out of which 0 drug patents have expired.

Valchlor was authorised for market use on 23 August, 2013.

Valchlor is available in gel;topical dosage forms.

Valchlor can be used as alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy.

The generics of Valchlor are possible to be released after 08 July, 2029.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501819	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Mar, 2026 (3 years from now)
US9382191	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Mar, 2026 (3 years from now)
US8450375	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Mar, 2026 (3 years from now)
US8501818	HELSINN	Stabilized compositions of alkylating agents and methods of using same	Mar, 2026 (3 years from now)
US7838564	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Mar, 2026 (3 years from now)
US7872050	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Jul, 2029 (6 years from now)

Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy

Dosage: GEL;TOPICAL